These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 1521921)
1. Enhanced induction of lymphokine-activated killer activity after lentinan administration in patients with gastric carcinoma. Arinaga S; Karimine N; Takamuku K; Nanbara S; Inoue H; Nagamatsu M; Ueo H; Akiyoshi T Int J Immunopharmacol; 1992 May; 14(4):535-9. PubMed ID: 1521921 [TBL] [Abstract][Full Text] [Related]
2. Augmentation of lymphokine-activated killer cell activity by lentinan. Tani M; Tanimura H; Yamaue H; Tsunoda T; Iwahashi M; Noguchi K; Tamai M; Hotta T; Mizobata S Anticancer Res; 1993; 13(5C):1773-6. PubMed ID: 8267381 [TBL] [Abstract][Full Text] [Related]
3. Induction of endogenous lymphokine-activated killer activity by combined administration of lentinan and interleukin 2. Suzuki M; Higuchi S; Taki Y; Taki S; Miwa K; Hamuro J Int J Immunopharmacol; 1990; 12(6):613-23. PubMed ID: 2272726 [TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients. Karimine N; Nanbara S; Arinaga S; Asoh T; Ueo H; Akiyoshi T J Surg Oncol; 1994 Mar; 55(3):179-85. PubMed ID: 8176929 [TBL] [Abstract][Full Text] [Related]
5. Enhanced production of interleukin 1 and tumor necrosis factor by peripheral monocytes after lentinan administration in patients with gastric carcinoma. Arinaga S; Karimine N; Takamuku K; Nanbara S; Nagamatsu M; Ueo H; Akiyoshi T Int J Immunopharmacol; 1992 Jan; 14(1):43-7. PubMed ID: 1582733 [TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer cell function of peripheral blood mononuclear cells, spleen cells and regional lymph node cells in gastric cancer patients. Karimine N; Arinaga S; Inoue H; Nanbara S; Ueo H; Akiyoshi T Clin Exp Immunol; 1994 Jun; 96(3):484-90. PubMed ID: 8004819 [TBL] [Abstract][Full Text] [Related]
7. Enhanced induction of lymphokine-activated killer activity following a single dose of cisplatin in cancer patients. Arinaga S; Adachi M; Karimine N; Inoue H; Asoh T; Ueo H; Akiyoshi T Int J Immunopharmacol; 1994 Jul; 16(7):519-24. PubMed ID: 7928001 [TBL] [Abstract][Full Text] [Related]
8. Lymphokine-activated killer cell function of lymphocytes from regional lymph nodes in patients with gastric carcinoma. Arinaga S; Karimine N; Nanbara S; Inoue H; Nakashima H; Ueo H; Akiyoshi T J Surg Oncol; 1995 Jan; 58(1):44-9. PubMed ID: 7823572 [TBL] [Abstract][Full Text] [Related]
9. [Study on the enhancing effect of polyporus polysaccharide, mycobacterium polysaccharide and lentinan on lymphokine-activated killer cell activity in vitro]. Li JF; Guo JW; Huang XF Zhongguo Zhong Xi Yi Jie He Za Zhi; 1996 Apr; 16(4):224-6. PubMed ID: 9206247 [TBL] [Abstract][Full Text] [Related]
10. Augmentation of human lymphokine-activated killer cell activity in splenic lymphocytes by the combination of low-dose interleukin 2 plus interleukin 3. Okuno K; Ohnishi H; Shilayama Y; Hirohata T; Ozaki M; Yasutomi M Mol Biother; 1992 Jun; 4(2):83-6. PubMed ID: 1515099 [TBL] [Abstract][Full Text] [Related]
11. Defective immunological functions associated with abnormal lymphokine-activated killer activity in patients with hepatocellular carcinoma. Shirai M; Watanabe S; Nishioka M J Gastroenterol Hepatol; 1990; 5(5):542-8. PubMed ID: 1966592 [TBL] [Abstract][Full Text] [Related]
12. Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma. Yamamoto RS; Coss J; Vayuvegula B; Gupta S; Beamer Y; Jacques S; Jeffes EW; Carson WE; Jakowatz J; Granger GA J Immunol Methods; 1991 Mar; 137(2):225-35. PubMed ID: 2013699 [TBL] [Abstract][Full Text] [Related]
13. [Clinical effects and immunological analysis of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion of gastric carcinoma]. Hazama S; Oka M; Yoshino S; Iizuka N; Wadamori K; Yamamoto K; Hirazawa K; Wang F; Ogura Y; Masaki Y Gan To Kagaku Ryoho; 1995 Sep; 22(11):1595-7. PubMed ID: 7574768 [TBL] [Abstract][Full Text] [Related]
14. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes. Flexman JP; Manning LS; Robinson BW Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789 [TBL] [Abstract][Full Text] [Related]
15. Isolation of human NK cells and generation of LAK activity. Whiteside TL Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847 [TBL] [Abstract][Full Text] [Related]
16. Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients. Nanbara S; Arinaga S; Akiyoshi T Cancer Immunol Immunother; 1989; 29(4):237-41. PubMed ID: 2568886 [TBL] [Abstract][Full Text] [Related]
17. Activated killer cell activity of spleen cells from patients with gastric carcinoma. Akiyoshi T; Koba F; Arinaga S; Tsuji H J Clin Lab Immunol; 1987 Aug; 23(4):197-201. PubMed ID: 2959788 [TBL] [Abstract][Full Text] [Related]
18. Synergistic induction of lymphokine (IL-2)-activated killer activity by IL-2 and the polysaccharide lentinan, and therapy of spontaneous pulmonary metastases. Yamasaki K; Sone S; Yamashita T; Ogura T Cancer Immunol Immunother; 1989; 29(2):87-92. PubMed ID: 2785852 [TBL] [Abstract][Full Text] [Related]